Q-omics provides the consensus-scored IGLVV-58 profile across patient tissues and cancer cell-line models. IGLVV-58 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IGLVV-58 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, IGLVV-58 RNA expression shows 5,117 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, LUSC, and STAD as cancer lineages where IGLVV-58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLVV-58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLVV-58 survival associations across molecular data types. IGLVV-58 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLVV-58 RNA expression–survival associations across cancer types. High IGLVV-58 expression shows unfavorable associations in UVM, UCS and STAD, but favorable associations in SKCM, PAAD and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IGLVV-58 RNA expression.
This table summarizes IGLVV-58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for IGLVV-58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLVV-58 shows lower tumor expression in KIRC and higher tumor expression in LUSC. The LUSC box plot shows higher IGLVV-58 RNA expression in tumor versus normal tissue (log2 FC = +0.145, t-test p = .020).
This table shows molecular features associated with IGLVV-58 in patient tissues and cancer cell lines. In patient samples, IGLVV-58 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
